Winson Tang MD is a well-travelled medical professional with a wealth of experience in clinical research. Between 2008 and 2009, he worked as a Medical Consultant for Amsterdam Molecular Therapeutics, where he as was chiefly responsible for the Phase 2/3 registration trial of the company's Glybera orphan drug for lipoprotein lipase deficiency. He was also instrumental in the development of the product profile for Glybera.